Skip to main content
SpringerLink
Log in

The Use of Pharmacologic Agents for Benign Prostatic Hyperplasia

  • Chapter
Benign Prostatic Hyperplasia

  • 112 Accesses

Abstract

It is generally accepted that transurethral prostatectomy (TURP) is an effective treatment for bladder outlet obstruction caused by benign prostatic hyperplasia (BPH); however, alternative therapies, in particular medical therapies, have been motivated by patients trying to avoid surgery, pharmaceutical companies expanding into new markets and physicians trying to optimize the treatment of their patients. Beyond these motivations, a critical review of TURP suggests that it is a good procedure but has associated complications in a low but predictable percentage of cases. Mebust et al. (1989) studied the morbidity following TURP in a cooperative retrospective study of 3885 consecutive patients from 13 institutions. Holtgrewe et al. (1989) surveyed practicing urologists in the United States with regard to morbidity and mortality. These results are summarized in Table 12.1. although relatively uncommon, the complications from TURP are significant (see Chap. 8).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bartsch G, Muller HR, Oberholzer M, et al. (1979) Light microscopic stereological analysis of the normal human prostate and benign prostatic hyperplasia. J Urol 122:487–491

    PubMed  CAS  Google Scholar 

  • Caine M, Perlberg S, Gordon R (1975a) The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo controlled study. J Urol 114:564–568

    PubMed  CAS  Google Scholar 

  • Caine M, Raz S, Ziegler M (1975b) Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck. Br J Urol 27:193–202

    Article  Google Scholar 

  • Caine M, Pfau A, Perlberg S (1976) The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol 48:255–263

    PubMed  CAS  Google Scholar 

  • Caine M, Perlberg S, Mertyk S (1978) A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50:551–555

    Article  PubMed  CAS  Google Scholar 

  • Caine M, Perlberg S, Shapiro A (1981) Phenoxybenzamine for benign prostatic obstruction: A review of 200 cases. Urology 25:542–546

    Article  Google Scholar 

  • Dorflinger T, Oster M, Larsen JF, et al. (1987) Transurethral prostatectomy or incision of the prostate in the treatment of prostatism caused by small benign prostates. Scand J Urol Nephrol 104:77–81

    CAS  Google Scholar 

  • Dorflinger T, England DM, Madsen PO, et al. (1989) Urodynamic and histological correlations of benign prostatic hypertrophy. Br J Urol 140:1487–1490

    Google Scholar 

  • Dunzenndorfer U (1987) Clinical experience: symptomatic management of BPH with terazosin. Urology 32:27–31

    Google Scholar 

  • Fabricius PG, Weizert P, Dunzendorger V, et al. (1990) Efficacy of once-a-day terazosin in benign prostatic hyperplasia. Prostate 3 (Suppl): 85–93

    Article  CAS  Google Scholar 

  • Gormley GJ, Stoner E, Brüskewitz RC, et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185–1191

    Article  PubMed  CAS  Google Scholar 

  • Guess HA, Heyse JF, Gormley GJ (1993) The effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate 22:31–37

    Article  PubMed  CAS  Google Scholar 

  • Gup DI, Shapiro E, Baumann M, et al. (1989) The contractile properties of human prostatic adenomas are unrelated to the development of intravesical obstruction. Prostate 15:105–114

    Article  PubMed  CAS  Google Scholar 

  • Gup DI, Shapiro E, Baumann M, et al. (1990) Autonomic receptors in asymptomatic and symptomatic BPH. J Urol 143:179–185

    PubMed  CAS  Google Scholar 

  • Hellstrom P, Lukkarinen O, Kontturi M (1986) Bladder neck incision or transurethral electroresec- tion for the treatment of urinary obstruction caused by a small prostate. Scand J Urol Nephrol 20:187–192

    Article  PubMed  CAS  Google Scholar 

  • Hieble JP, Caine M, Zalaznik E (1985) In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol 107:111–117

    Article  PubMed  CAS  Google Scholar 

  • Holtgrewe HL, Mebust WK, Dowd JB, et al. (1989) Transurethral prostatectomy: practice aspects of the dominant operation in American Urology. J Urol 141:248–253

    PubMed  CAS  Google Scholar 

  • Lepor H, Machi GM (1992) The combination of terazosin and flutamide for symptomatic BPH. Prostate 20:89–95

    Article  PubMed  CAS  Google Scholar 

  • Lepor H, Riguad G (1990) The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 143:533–537

    PubMed  CAS  Google Scholar 

  • Lepor H, Shapiro E (1984) Characterization of alphax adrenoceptors in human benign prostatic hyperplasia. J Urol 132:1226–1229

    PubMed  CAS  Google Scholar 

  • Lepor H, Baumann M, Shapiro E (1988) The stereospecificity of LY253352 for alpha x blockade in prostatic hyperplasia. Br J Pharmacol 95:139–144

    PubMed  CAS  Google Scholar 

  • Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J (1989) The safety and efficacy of terazosin for the treatment of BPH. Int J Clin Pharmacol Ther Toxicol 27:392–397

    PubMed  CAS  Google Scholar 

  • Lepor H, Knapp-Maloney G, Sunshine H (1990) An open-label dose titration study evaluating terazosin for the treatment of symptomatic BPH. J Urol 144:1393–1398

    PubMed  CAS  Google Scholar 

  • Lepor H, Henry D, Laddu AR (1991) The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate 18:345–356

    Article  PubMed  CAS  Google Scholar 

  • Lepor H, Auerbach S, Puras-Baez A, et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148:1467–1474

    PubMed  CAS  Google Scholar 

  • Mebust WK, Holtgrewe HL, Cockett ATK, et al. (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 141:243–247

    PubMed  CAS  Google Scholar 

  • Neal DE, Ramsden PD, Sharpies L, et al. (1989) Outcome of elective prostatectomy. Br Med J 299:762–767

    Article  CAS  Google Scholar 

  • Orandi A (1987) Transurethral incision of prostate compared with transurethral resection of the prostate in 132 matching cases. J Urol 138:810–815

    PubMed  CAS  Google Scholar 

  • Peters CA, Walsh PC (1987) The effect of nafareline acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317:599–604

    Article  PubMed  CAS  Google Scholar 

  • Raz S, Ziegler M, Caine M (1973) Pharmacologic receptors in the prostate. Br J Urol 45:663–667

    Article  PubMed  CAS  Google Scholar 

  • Shapiro E, Lepor H (1987) Alpha adrenergic receptors in canine lower genitourinary tissues: insight into development and function. J Urol 138:979–983

    PubMed  CAS  Google Scholar 

  • Shapiro E, Lepor H (1992) The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21:297–307

    Article  PubMed  CAS  Google Scholar 

  • Shapiro E, Hartanto V, Lepor H (1992a) Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle. Prostate, 20:259–268

    Article  PubMed  CAS  Google Scholar 

  • Shapiro E, Hartanto V, Lepor H (1992b) Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 147: 1167–1170

    PubMed  CAS  Google Scholar 

  • Stone MM (1989) Flutamide in treatment of benign prostatic hypertrophy. Urology 34(4): 64–68

    Article  PubMed  CAS  Google Scholar 

  • The Proscar Study Group (1990) Treatment of benign prostatic hyperplasia (BPH) with Proscar, a 5alpha reductase (5aR) inhibitor. Abstract of workshop conference on androgen therapy: biologic and clinical consequences. January 17, Marco Island, FL

    Google Scholar 

  • Wennberg JE, Roos N, Sola L, et al. (1987) Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 257:933–936

    Article  PubMed  CAS  Google Scholar 

  • White JW (1895) The result of double castration in hypertrophy of the prostate. Ann Surg 22:1—80

    PubMed  Google Scholar 

  • Wu J, Gu F (1987) The prostate 41–65 years post castration: an analysis of 26 eunuchs. Chin Med J 100:271

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, New York University, 550 First Avenue, 10016, New York, New York, USA

    Christopher M. Dixon MD (Assistant Professor) & Herbert Lepor MD, FACS (Professor and Chairman)

Authors
  1. Christopher M. Dixon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert Lepor MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Kenneth Norris Jr. Cancer Center, University of Southern California, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA

    Zbigniew Petrovich MD (Professor and Chairman) (Professor and Chairman)

  2. Department of Urology, St. Pieter’s Hospital, Catholic University of Leuven, Brusselsestraat 69, 3000, Leuven, Belgium

    Luc Baert MD, PhD (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology) (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology)

  3. School of Medicine, University of Southern California, 90033, Los Angeles, CA, USA

    Luc Baert MD, PhD (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology) (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dixon, C.M., Lepor, H. (1994). The Use of Pharmacologic Agents for Benign Prostatic Hyperplasia. In: Petrovich, Z., Baert, L. (eds) Benign Prostatic Hyperplasia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78185-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78185-8_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78187-2

  • Online ISBN: 978-3-642-78185-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation